ABBV — Abbvie Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual cashflow statement for Abbvie, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	4,622	11,549	11,845	4,873	4,286
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	8,714	4,927	6,820	9,344	10,365
Unusual Items
Other Non-Cash Items
Changes in Working Capital	106	-1,322	-258	2,813	-2,782
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Cash from Operating Activities	17,588	22,777	24,943	22,839	18,806
Capital Expenditures	-798	-787	-695	-777	-974
Purchase of Fixed Assets
Other Investing Cash Flow Items	-36,759	-1,557	72	-1,232	-19,846
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-37,557	-2,344	-623	-2,009	-20,820
Financing Cash Flow Items	-333	-674	-1,102	-742	-42
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-11,501	-19,039	-24,803	-17,222	-5,211
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-31,475	1,297	-545	3,613	-7,290